21 results for author:"Van den Steen P.E." in Literature citations
Results Customize
› Repeat search in UniProtKB (1)
| Insufficiently defined genetic background confounds phenotypes in transgenic studies as exemplified by malaria infection in Tlr9 knockout mice. Geurts N., Martens E., Verhenne S., Lays N., Thijs G., Magez S., Cauwe B., Li S., Heremans H., Opdenakker G. et al. PLoS ONE 6:e27131-e27131(2011) · Mapped (1) |
| Natural haemozoin modulates matrix metalloproteinases and induces morphological changes in human microvascular endothelium. Prato M., D'Alessandro S., Van den Steen P.E., Opdenakker G., Arese P., Taramelli D., Basilico N. Cell. Microbiol. 13:1275-1285(2011) · Mapped (13) |
| Deficiency of gelatinase B/MMP-9 aggravates lpr-induced lymphoproliferation and lupus-like systemic autoimmune disease. Cauwe B., Martens E., Sagaert X., Dillen C., Geurts N., Li S., Mertens J., Thijs G., Van den Steen P.E., Heremans H. et al. J. Autoimmun. 36:239-252(2011) · Mapped (7) |
| Matrix metalloproteinase-9 promotes chronic lymphocytic leukemia b cell survival through its hemopexin domain. Redondo-Munoz J., Ugarte-Berzal E., Terol M.J., Van den Steen P.E., Hernandez del Cerro M., Roderfeld M., Roeb E., Opdenakker G., Garcia-Marco J.A., Garcia-Pardo A. Cancer Cell 17:160-172(2010) · Mapped (7) |
| Neutrophil MMP-9 proenzyme, unencumbered by TIMP-1, undergoes efficient activation in vivo and catalytically induces angiogenesis via a basic fibroblast growth factor (FGF-2)/FGFR-2 pathway. Ardi V.C., Van den Steen P.E., Opdenakker G., Schweighofer B., Deryugina E.I., Quigley J.P. J. Biol. Chem. 284:25854-25866(2009) · Mapped (23) |
| The collagen binding domain of gelatinase A modulates degradation of collagen IV by gelatinase B. Gioia M., Monaco S., Van Den Steen P.E., Sbardella D., Grasso G., Marini S., Overall C.M., Opdenakker G., Coletta M. J. Mol. Biol. 386:419-434(2009) · Mapped (11) |
| Adenylyl cyclase-associated protein-1/CAP1 as a biological target substrate of gelatinase B/MMP-9. Cauwe B., Martens E., Van den Steen P.E., Proost P., Van Aelst I., Blockmans D., Opdenakker G. Exp. Cell Res. 314:2739-2749(2008) · Mapped (18) |
| CXCR3 determines strain susceptibility to murine cerebral malaria by mediating T lymphocyte migration toward IFN-gamma-induced chemokines. Van den Steen P.E., Deroost K., Van Aelst I., Geurts N., Martens E., Struyf S., Nie C.Q., Hansen D.S., Matthys P., Van Damme J. et al. Eur. J. Immunol. 38:1082-1095(2008) · Mapped (12) |
| Alpha4beta1 integrin and 190-kDa CD44v constitute a cell surface docking complex for gelatinase B/MMP-9 in chronic leukemic but not in normal B cells. Redondo-Munoz J., Ugarte-Berzal E., Garcia-Marco J.A., del Cerro M.H., Van den Steen P.E., Opdenakker G., Terol M.J., Garcia-Pardo A. Blood 112:169-178(2008) · Mapped (23) |
| Beta-hematin interaction with the hemopexin domain of gelatinase B/MMP-9 provokes autocatalytic processing of the propeptide, thereby priming activation by MMP-3. Geurts N., Martens E., Van Aelst I., Proost P., Opdenakker G., Van den Steen P.E. Biochemistry 47:2689-2699(2008) · Mapped (9) |
| Insights into the structure and domain flexibility of full-length pro-matrix metalloproteinase-9/gelatinase B. Rosenblum G., Van den Steen P.E., Cohen S.R., Grossmann J.G., Frenkel J., Sertchook R., Slack N., Strange R.W., Opdenakker G., Sagi I. Structure 15:1227-1236(2007) · Mapped (7) |
| Hemopexin domains as multifunctional liganding modules in matrix metalloproteinases and other proteins. Piccard H., Van den Steen P.E., Opdenakker G. J. Leukoc. Biol. 81:870-892(2007) · Mapped (3) |
| Cancer-associated glycoforms of gelatinase B exhibit a decreased level of binding to galectin-3. Fry S.A., Van den Steen P.E., Royle L., Wormald M.R., Leathem A.J., Opdenakker G., McDonnell J.M., Dwek R.A., Rudd P.M. Biochemistry 45:15249-15258(2006) · Mapped (7) |
| A monoclonal antibody inhibits gelatinase B/MMP-9 by selective binding to part of the catalytic domain and not to the fibronectin or zinc binding domains. Martens E., Leyssen A., Van Aelst I., Fiten P., Piccard H., Hu J., Descamps F.J., Van den Steen P.E., Proost P., Van Damme J. et al. Biochim. Biophys. Acta 1770:178-186(2007) · Mapped (7) |
| The hemopexin and O-glycosylated domains tune gelatinase B/MMP-9 bioavailability via inhibition and binding to cargo receptors. Van den Steen P.E., Van Aelst I., Hvidberg V., Piccard H., Fiten P., Jacobsen C., Moestrup S.K., Fry S., Royle L., Wormald M.R. et al. J. Biol. Chem. 281:18626-18637(2006) · Mapped (7) |
| Gelatinase B/matrix metalloproteinase-9 provokes cataract by cleaving lens betaB1 crystallin. Descamps F.J., Martens E., Proost P., Starckx S., Van den Steen P.E., Van Damme J., Opdenakker G. FASEB J. 19:29-35(2005) · Mapped (5) |
| Generation of glycosylated remnant epitopes from human collagen type II by gelatinase B. Van den Steen P.E., Proost P., Brand D.D., Kang A.H., Van Damme J., Opdenakker G. Biochemistry 43:10809-10816(2004) · Mapped (7) |
| Carboxyterminal cleavage of the chemokines MIG and IP-10 by gelatinase B and neutrophil collagenase. Van den Steen P.E., Husson S.J., Proost P., Van Damme J., Opdenakker G. Biochem. Biophys. Res. Commun. 310:889-896(2003) · Mapped (14) |
| A novel rationale for inhibition of gelatinase B in multiple sclerosis: MMP-9 destroys alpha B-crystallin and generates a promiscuous T cell epitope. Starckx S., Van den Steen P.E., Verbeek R., van Noort J.M., Opdenakker G. J. Neuroimmunol. 141:47-57(2003) · Mapped (3) |
| Neutrophil gelatinase B and chemokines in leukocytosis and stem cell mobilization. Starckx S., Van den Steen P.E., Wuyts A., Van Damme J., Opdenakker G. Leuk. Lymphoma 43:233-241(2002) · Mapped (8) |
| Neutrophil gelatinase B potentiates interleukin-8 tenfold by aminoterminal processing, whereas it degrades CTAP-III, PF-4, and GRO-alpha and leaves RANTES and MCP-2 intact. Van den Steen P.E., Proost P., Wuyts A., Van Damme J., Opdenakker G. Blood 96:2673-2681(2000) · UniProtKB (1) |